Twist Bioscience Corporation logo

Twist Bioscience Corporation

TWST | NASDAQ
Chart Builder DCF Calculator
$142.74
-$10.04 (-6.57%)
Nov 2, 2026, 10:32 AM ET · Market open

Company Profile

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Key Executives

Name Position
Emily Marine Leproust Co-Founder, Board Chair & Chief Executive Officer
Adam Laponis Chief Financial Officer
Dennis Cho Chief Legal Officer & Corporate Secretary
Michael Fero Chief Information Officer
Patrick John Finn President & Chief Operating Officer
Siyuan Chen Chief Technology Officer
Colby Souders Chief Scientific Officer
Nicole Moreno Senior Vice President of Sales & Support
Paula Green Senior Vice President of Human Resources
Robert F. Werner Vice President & Chief Accounting Officer

Latest SEC Filings

Date Type Title
Sep 25, 2026 4 Filing
Sep 23, 2026 4 Filing
Sep 23, 2026 4 Filing
Sep 23, 2026 4 Filing
Sep 21, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 08, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Twist Bioscience Corporation
Twist Bioscience Corporation logo
Country United States
IPO Date Oct 31, 2018
Industry Biotechnology
Sector Healthcare
Employees 979
CEO Emily Marine Leproust

Contact Details

681 Gateway Boulevard South San Francisco, California 94080 United States

Stock Details

Ticker Symbol TWST
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001581280
CUSIP Number 90184D100
ISIN Number US90184D1000
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.